×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CYTK – cytokinetics, incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CYTK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
09:06 pm
cytk
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
Low
Report
Cytokinetics, Incorporated (CYTK): A Bull Case Theory [Yahoo! Finance]
2/3
08:12 am
cytk
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Truist Financial Corporation from $84.00 to $92.00. They now have a "buy" rating on the stock.
1/28
08:06 am
cytk
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
Low
Report
Cytokinetics' heart drug hits market after FDA approval [FOX Business Network]
1/28
08:03 am
cytk
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
Low
Report
Cytokinetics (NASDAQ:CYTK) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $87.00 price target on the stock.
1/27
01:39 pm
cytk
How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]
Low
Report
How MYQORZO's REMS-Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors [Yahoo! Finance]
1/27
10:07 am
cytk
Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
Low
Report
Olympian Sydney McLaughlin-Levrone is letting track take a backseat [USA TODAY]
1/27
08:00 am
cytk
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
Low
Report
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
1/27
07:30 am
cytk
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Low
Report
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:00 pm
cytk
cytokinetics, incorporated
MISS
Report
1.9%
cytokinetics, incorporated
8/7/2025
04:00 pm
cytk
cytokinetics, incorporated
BEAT
Report
-3.2%
cytokinetics, incorporated
5/6/2025
04:00 pm
cytk
cytokinetics, incorporated
BEAT
Report
-2.7%
cytokinetics, incorporated
2/27/2025
04:00 pm
cytk
cytokinetics, incorporated
MISS
Report
-3.1%
cytokinetics, incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/5
08:17 pm
cytk
Form 4 CYTOKINETICS INC For: Feb 05 Filed by: Callos Andrew
Medium
Report
Form 4 CYTOKINETICS INC For: Feb 05 Filed by: Callos Andrew
2/2
04:41 pm
cytk
Form 4 CYTOKINETICS INC For: Feb 02 Filed by: Callos Andrew
Low
Report
Form 4 CYTOKINETICS INC For: Feb 02 Filed by: Callos Andrew
1/20
04:17 pm
cytk
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Daly James M
Low
Report
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Daly James M
1/16
04:22 pm
cytk
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Wysenski Nancy
Low
Report
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Wysenski Nancy
1/16
04:21 pm
cytk
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: WIERENGA WENDELL
Low
Report
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: WIERENGA WENDELL
1/16
04:19 pm
cytk
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Kaye Edward M. MD
Low
Report
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Kaye Edward M. MD
1/16
04:17 pm
cytk
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: HENDERSON JOHN T
Low
Report
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: HENDERSON JOHN T
1/16
04:16 pm
cytk
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Harrington Robert Arthur
Low
Report
Form 4 CYTOKINETICS INC For: Jan 15 Filed by: Harrington Robert Arthur
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/12
Form 4 CYTOKINETICS INC For: Dec 10 Filed by: BVF INC/IL
12.1%
5/9 Form 8-K CYTOKINETICS INC For: May 09 11.8%
2/14 Form SC 13G/A CYTOKINETICS INC Filed by: Point72 Asset Management, L.P. 10.3%
11/18 Form 4 CYTOKINETICS INC For: Nov 15 Filed by: Blum Robert I 10.3%
5/6 Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch] 9.6%
4/8 Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference 8.9%
3/30 Form DEFA14A CYTOKINETICS INC 8.9%
1/13 Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones 8.0%
4/1 Form SC 13G/A CYTOKINETICS INC Filed by: BIOTECHNOLOGY VALUE FUND L P 6.3%
8/16 Cytokinetics, Inc. (NASDAQ: CYTK) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 6.2%
5/9 Form 8-K CYTOKINETICS INC For: May 09 11.8%
2/14 Form SC 13G/A CYTOKINETICS INC Filed by: Point72 Asset Management, L.P. 10.3%
11/18 Form 4 CYTOKINETICS INC For: Nov 15 Filed by: Blum Robert I 10.3%
5/6 Cytokinetics plunges 19% after Phase 2 trial of ALS drug fails to meet endpoints [MarketWatch] 9.6%
4/8 Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference 8.9%
3/30 Form DEFA14A CYTOKINETICS INC 8.9%
1/13 Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones 8.0%
4/1 Form SC 13G/A CYTOKINETICS INC Filed by: BIOTECHNOLOGY VALUE FUND L P 6.3%
8/16 Cytokinetics, Inc. (NASDAQ: CYTK) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 6.2%
TOP News Decliners
11/6
Edited Transcript of CYTK earnings conference call or presentation 31-Oct-19 8:30pm GMT [Yahoo! Finance News]
-23.6%
11/8 Form 305B2 CYTOKINETICS INC -11.2%
3/6 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
9/6 Form 4 CYTOKINETICS INC For: Sep 05 Filed by: Malik Fady Ibraham -10.1%
5/22 Form 3 CYTOKINETICS INC For: May 15 Filed by: Wong Robert -9.5%
12/16 Cytokinetics: Big Insider Buying By Beneficial Owner [Seeking Alpha] -9.2%
4/29 Form 4 CYTOKINETICS INC For: Apr 28 Filed by: WIERENGA WENDALL -7.2%
4/1 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.4%
1/23 Form SC 13G/A CYTOKINETICS INC Filed by: INTEGRATED CORE STRATEGIES (US) LLC -5.1%
12/18 Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis -5.1%
11/8 Form 305B2 CYTOKINETICS INC -11.2%
3/6 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
9/6 Form 4 CYTOKINETICS INC For: Sep 05 Filed by: Malik Fady Ibraham -10.1%
5/22 Form 3 CYTOKINETICS INC For: May 15 Filed by: Wong Robert -9.5%
12/16 Cytokinetics: Big Insider Buying By Beneficial Owner [Seeking Alpha] -9.2%
4/29 Form 4 CYTOKINETICS INC For: Apr 28 Filed by: WIERENGA WENDALL -7.2%
4/1 Cytokinetics, Inc. (NASDAQ: CYTK) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.4%
1/23 Form SC 13G/A CYTOKINETICS INC Filed by: INTEGRATED CORE STRATEGIES (US) LLC -5.1%
12/18 Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis -5.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: